At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 8 enrolled
Drug / intervention
No Interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Single-Time Blood Sample Collection Study for Pharmacogenomic Characterization of Subjects That Previously Received Namilumab and Participated in the Phase 1 PRIORA Study
In Brief
A Phase 1 clinical trial evaluating No Intervention for Rheumatoid Arthritis. Completed, enrolled 8 participants.
Detailed Summary
The purpose of this study is to obtain blood samples from up to 14 participants who previously received namilumab in the previous study M1-1188-002-EM (PRIORA, \[NCT01317797\]) to correlate genetic markers with clinical outcomes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartNov 2015
Primary CompletionApr 2016
TodayJul 2026
First PostedAug 19, 2015
Enrollment StartNov 19, 2015
Primary CompletionApr 5, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 10.9 years ago
Interventions
No Interventionother
No study drug will be administered in this study.